BRPI0410767A - formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores - Google Patents

formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores

Info

Publication number
BRPI0410767A
BRPI0410767A BRPI0410767-5A BRPI0410767A BRPI0410767A BR PI0410767 A BRPI0410767 A BR PI0410767A BR PI0410767 A BRPI0410767 A BR PI0410767A BR PI0410767 A BRPI0410767 A BR PI0410767A
Authority
BR
Brazil
Prior art keywords
agents
small particle
attack
pharmaceutical formulations
dementing
Prior art date
Application number
BRPI0410767-5A
Other languages
English (en)
Inventor
Rabinow E Barrett
Jane Werling
Jamie Teresa Konkel
Mark J Doty
Christine L Rebbeck
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of BRPI0410767A publication Critical patent/BRPI0410767A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS DE PARTìCULA PEQUENA DE AGENTES ANTIATAQUE E ANTIDEMêNCIA E AGENTES IMUNOSSUPRESSORES". A presente invenção refere-se à formulação de suspensões de partícula pequena de anticonvulsivos e antidemência, particularmente carbamazepina, para uso farmacêutico. A presente invenção refere-se à formulação de suspensões de partícula pequena de agentes imunossupressores, particularmente ciclosporina, para uso farmacêutico.
BRPI0410767-5A 2003-05-19 2004-05-19 formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores BRPI0410767A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47158103P 2003-05-19 2003-05-19
PCT/US2004/015621 WO2004103348A2 (en) 2003-05-19 2004-05-19 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers

Publications (1)

Publication Number Publication Date
BRPI0410767A true BRPI0410767A (pt) 2006-07-04

Family

ID=33476859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410767-5A BRPI0410767A (pt) 2003-05-19 2004-05-19 formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores

Country Status (11)

Country Link
US (1) US20050244503A1 (pt)
EP (1) EP1628641A2 (pt)
JP (1) JP2006528985A (pt)
KR (1) KR20060012628A (pt)
CN (1) CN1791386A (pt)
AU (1) AU2004240640A1 (pt)
BR (1) BRPI0410767A (pt)
CA (1) CA2524538A1 (pt)
MX (1) MXPA05012467A (pt)
NO (1) NO20056020L (pt)
WO (1) WO2004103348A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274341T1 (de) * 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US9044381B2 (en) * 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
KR20070116581A (ko) * 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
CA2601312A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
BRPI0609071A2 (pt) * 2005-04-12 2010-11-16 Elan Pharma Int Ltd composicão estável de ciclosporina nanoparticulada, método para preparar uma ciclosporina nanoparticulada, uso da composição de ciclosporina nanoparticulada estável, e, composição de liberação controlada
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20090098207A1 (en) * 2007-07-24 2009-04-16 Nexbio, Inc. Technology for the Preparation of Microparticles
US9364443B2 (en) * 2008-03-05 2016-06-14 Baxter International, Inc. Compositions and methods for drug delivery
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US8969414B2 (en) 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
EA022700B1 (ru) 2009-12-10 2016-02-29 Мерк Патент Гмбх Фармацевтическая композиция, содержащая олигопептиды
US10307372B2 (en) * 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CN103717205B (zh) 2011-06-09 2017-04-12 默克专利股份公司 用西仑吉肽在载体中的悬浮液治疗癌症和癌症转移
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
WO2014005103A2 (en) 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
MX2020004912A (es) 2013-10-25 2021-05-21 Insmed Inc Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar.
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
CN108135838A (zh) * 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
WO2018195186A1 (en) * 2017-04-18 2018-10-25 Marinus Pharmaceuticals, Inc Sustained release injectable neurosteroid formulations
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
CA3138530A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5720551A (en) * 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DK0929293T3 (da) * 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse
JP3884484B2 (ja) * 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー 吸入用粒子の調製
WO1999049846A2 (en) * 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
BR9909736A (pt) * 1998-04-18 2000-12-19 Glaxo Group Ltd Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
PT1169019E (pt) * 1999-04-14 2003-07-31 Glaxo Group Ltd Formulacao farmaceutica em aerossol
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems

Also Published As

Publication number Publication date
AU2004240640A1 (en) 2004-12-02
NO20056020L (no) 2005-12-16
KR20060012628A (ko) 2006-02-08
MXPA05012467A (es) 2006-02-22
CA2524538A1 (en) 2004-12-02
CN1791386A (zh) 2006-06-21
US20050244503A1 (en) 2005-11-03
WO2004103348A3 (en) 2005-01-06
JP2006528985A (ja) 2006-12-28
EP1628641A2 (en) 2006-03-01
WO2004103348A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
BRPI0410767A (pt) formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores
BR9902086A (pt) Formulações farmacêuticas.
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
BR0009083B1 (pt) derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
WO2001016135A3 (en) Reverse-turn mimetics and methods relating thereto
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
BR0205161A (pt) Pó de poliamida com valor do ph ajustado para empregos cosméticos
WO2007062338A3 (en) Solid formulations
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
BR0011030A (pt) Composições de cicloporina substancialmente livre de óleo
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
FR2827166B1 (fr) Mascara comprenant des particules solides
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
FR2827167B1 (fr) Mascara comprenant des particules solides
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
WO2005030142A3 (en) Rifalazil formulations
ITRM20020119A1 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
ITFI20050178A1 (it) Uso di metalloproteinasi di matrice, mutate e non, per la preparazione di composizioni farmaceutiche, e metalloproteinasi mutate aventi aumentata stabilita'
BRPI0415057A (pt) composições de limpeza
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
ES2193072T3 (es) Empleo cosmetico o farmaceutico de jabones metalicos a manoescala.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.